- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05413655
A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects With Mild Alzheimer's Disease
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Cliff Lin
- Phone Number: +886-972821234
- Email: cliff.lin@excelsiorgroup.com.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Pei-Ling Peng
- Phone Number: 65340 886-2-23123456
- Email: ho-ling@yahoo.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 50-80 years.
- Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011)
- Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-26.
- Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of 1.
Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria:
- AST, ALT level ≦ upper limit of normal
- Creatine Kinase (CK) concentration more than 3 times upper limit of normal
- Serum creatinine level ≦ upper limit of normal
- HbA1c more than 8.0
- Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities.
- Cognitive deficits caused impairment in social or occupational function.
- Disease progression with gradual and continued decline from a previous level of functioning.
- Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control.
- Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study.
Exclusion Criteria:
- Having other causes of dementia.
Having substantial concomitant cerebrovascular disease (defined by a history of a stroke
/ intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.
- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement:
- Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension.
- Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV.
- Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
- Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism.
- Unstable/Uncontrolled major depression.
- Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis).
- Significant pulmonary disease predisposing to hypoxia.
- Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease)
- Any other psychiatric disorders such as schizophrenia, or mental retardation.
- Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- Hachinski Ischemic Score > 4
- Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator)
- Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
- Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1000 mg
The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
|
The dosage form of EX039 is the capsule for oral use
|
Experimental: 750 mg
The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
|
The dosage form of EX039 is the capsule for oral use
|
Placebo Comparator: placebo
The recruited patient randomly assigned to this arm will take placebo per day
|
The dosage form of Placebo is the capsule for oral use
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alzheimer's Disease Assessment Scale-cognitive
Time Frame: Week 28
|
Mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale measured at the end of week 28.
Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.
|
Week 28
|
Change in Clinical Dementia Rating-Sum of Boxes
Time Frame: Week 28
|
Mean change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB).
measured at the end of week 28.
Total scores range from 0 to 18, with higher scores indicating more worsening.
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician's Interview-Based Impression of Change Plus Caregiver Input
Time Frame: Week 4, 12, 20, 28
|
Scorings of Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) at the end of week 4, 12, 20, and 28.
|
Week 4, 12, 20, 28
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Week 30
|
To assess the safety and tolerability of EX039
|
Week 30
|
Responder rate assessment
Time Frame: Week 28
|
The percentage of the recruited subjects whose mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) measured at the end of week 28 is improved (≧4) without deterioration of CDR-SB and CIBIS-Plus
|
Week 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ching-Kuan Liu, Dr., Kaohsiung Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX-039-10701
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States